From the Canadian Rheumatology Association (May 21, 2019):
As evidence for the benefits and risks of using biosimilars in the management of rheumatic diseases has grown rapidly, the Canadian Rheumatology Association (CRA) has updated its position statement on biosimilars accordingly. We have undertaken this initiative to ensure that you and your patients are in possession of up-to-date guidance regarding the use and potential benefits and risks of biosimilars so that informed and appropriate treatment decisions may be made.
Please join the CIBRN Leaders for Webinar 1 of 2019 on Wednesday, May 22 at 9:00 pm ET. The webinar will review the recent discussions and podcast in the CIBRN community:
CIBRN 2019 Q1: Should drug approvals be based on efficacy and demonstrated need, or should pharmacoeconomics be a larger consideration? [View 5 replies to date]
CIBRN 2019 Q2: Should manufacturers’ rebates be kept confidential, or should full transparency be expected, in order to more properly compare costs between originators and biosimilars? [View 4 replies to date]
CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18) [Listen to the podcast]
To connect to the webinar:
Step 1: Join the teleconference at 1-866-830-9434 and enter PIN 7994216
Welcome to the CIBRN Podcast channel. This year, we’ve decided to take a fresh approach to article reviews, providing timely and brief (3-5 minutes) podcasts on articles selected and reviewed by CIBRN members. The first in the series has been provided by Dr. Philip Baer.
CIBRN Podcast Episode 1: Dr. Philip Baer on “Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States.” Current Medical Research Opinion, April 2019, Teeple et al. (3:18)
We invite you to view the archived recording of the virtual review webinar which was held on September 20th, led by Dr. Gordon Searles featuring the recent article in Advances in Therapy by Numan et al: Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies[link to full text]